Healthcare professionals including rheumatologists, dermatologists, immunologists, internists, cardiologists, nephrologists, pulmonologists, neurologists, family physicians, nurses at clinics contracted to administer BENLYSTA, psychiatrists, psychologists, and pharmacists. In a recent post-marketing study (BEL115467), depression, suicidal ideation or behaviour, and self-injury were reported more frequently in patients receiving BENLYSTA plus standard therapy, when compared to patients taking placebo plus standard therapy

Healthcare professionals are advised to: Evaluate the risk of depression, suicidal ideation or behaviour, and self-injury before starting and during treatment with BENLYSTA. Advise patients and their caregivers to contact a healthcare provider if patients experience new or worsening depression, suicidal ideation or behaviour, or self-injury. Evaluate and refer patients experiencing new or worsening depression, suicidal ideation or behaviour, or self-injury to a mental health professional, as needed.